about
Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data.Pharmaceutical Use and Spending Trend in Medicare Beneficiaries With Dementia, From 2006 to 2012.Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries.Time to reconsider dabigatran 110 mg in the USA.Geographic Variation in the Use of Oral Anticoagulation Therapy in Stroke Prevention in Atrial Fibrillation.Comparing the Approval and Coverage Decisions of New Oncology Drugs in the United States and Other Selected Countries.Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation.Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.Using predictive analytics and big data to optimize pharmaceutical outcomes.Risk of bleeding with dabigatran in atrial fibrillation.Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline.Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.Comparing Adoption of Breakthrough and "Me-too" Drugs among Medicare Beneficiaries: A Case Study of Dipeptidyl Peptidase-4 Inhibitors.Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D BeneficiariesAccounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-ReplyAvoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidenceAssociation of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer DiseaseCardiac resynchronization therapy using pacemakers vs defibrillators in patients with nonischemic cardiomyopathy: The United States experience from 2007 to 2014Incidence of fracture events with teriparatide: role of study designEffectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial FibrillationCost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney functionComparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of BleedingRevisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor EvolocumabAdherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial FibrillationComparing state, regional, and local variation in concurrent opioid and benzodiazepine useThe Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of DrugsImpact of community pharmacist-provided preventive services on clinical, utilization, and economic outcomes: An umbrella reviewStatins for Primary Prevention of Cardiovascular DiseaseChanges in Drug Pricing After Drug Shortages in the United StatesAssessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of CompetitorsNumber of manufacturers and generic drug pricing from 2005 to 2017Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial FibrillationSavings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid DataTrends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part DLowering the P Value ThresholdInterpreting COVID-19 Test Results: a Bayesian Approach
P50
Q31131255-FA8F2FEA-0B9C-458B-9752-0C86C6FC1129Q33610481-11836300-D8D1-4A26-8D3A-A21E03FC9152Q35966238-F74E32B8-D407-4A15-BE5F-E7063C8147B4Q38526044-4ABBF4A3-8A88-44A5-8BAE-B0CDCC5AFDD2Q38665890-9E5D2929-4594-4CA2-8F0E-E5CE31AF853FQ38997569-75190FC9-53F6-4E2D-9D44-E71364AE2B1BQ39137944-572AFEB1-2A42-465C-A0FA-E1C1E12BB30DQ40852576-1F42369B-F1FA-4CBF-98E4-794F260DB368Q42345865-32F44122-B5E3-4F36-BA31-730FD30E20DFQ45939234-F7CDF1D5-C323-4B07-9676-6323F9B46CEBQ46183835-F162F5AF-B247-40A9-ADED-C116BDC6BE69Q47208240-453FA7E1-84C6-4C61-BAE9-13EB35B0EDCCQ50232126-5378524E-8F9B-4E76-A8A0-334863D0EB63Q52672012-3EF3B8EB-1FBF-4F4A-8E1A-61D53C3E28E9Q52715561-D11A69D3-9843-41CE-BD68-96B856AF79A8Q53050576-81C34327-6348-4BE3-A6D5-6C840A4AB6CCQ56626360-7C906FE3-4E05-4C23-8294-A0B110F895A3Q57476346-F77E1D0D-DD3B-4DD1-AC8B-479D7B662397Q60044051-561D7A14-26D7-4486-83C0-2B292594D4D8Q64081519-21E34897-2B60-45A8-8758-8316F44CDB97Q64110740-A9293190-78B0-44DA-A584-C925F1C7A052Q85410793-80FEFF54-9DC9-498E-81A1-147CF4C423F4Q88432923-1E05A1F5-6E2C-4C31-B754-03836AB57C28Q88608890-8CD27656-A9E3-414E-8D01-0A2B43694059Q88610928-DAAA7864-46BC-4946-A9E5-D74129B4E2FDQ88703872-F022A799-603C-4C88-A18F-978E5DBF2289Q90117699-5A6442FB-53C3-4E37-8E8D-0749822D265FQ90897192-5A848A3B-91D6-4BEF-963C-452293DC7179Q90921343-6E5D5A95-FE94-45BC-ABF6-3B2F81B9F8C6Q91141583-2BE60C1B-B770-495C-897E-FAF8E68F5925Q91515519-836778F0-5F48-4B03-AAA0-F44977341FCBQ91641076-5506ED5E-E720-45FF-9BA9-260D003445EAQ91675961-85E0380C-27F6-431D-8F41-4C46AA6FA162Q91987005-FE42D0A4-3211-411F-9AC4-8A1342E331EFQ92595050-680EDF0B-582D-437B-B391-8FE36304190BQ92687709-B1200BB8-F2C5-429E-8A3E-AE04CAC5DCAFQ92835913-2172A49F-259D-4531-B72E-12B60B71BA7AQ92865695-9566F396-7610-4D75-A185-F3BD1F5BBDEEQ95597125-6928DE4D-C405-4D20-A4E4-31B257C075EAQ96109990-C4413C1D-514C-4675-B06D-93D013468888
P50
description
researcher ORCID ID = 0000-0002-0118-4986
@en
name
Inmaculada Hernandez
@ast
Inmaculada Hernandez
@en
Inmaculada Hernandez
@es
Inmaculada Hernandez
@nl
Inmaculada Hernandez
@pl
type
label
Inmaculada Hernandez
@ast
Inmaculada Hernandez
@en
Inmaculada Hernandez
@es
Inmaculada Hernandez
@nl
Inmaculada Hernandez
@pl
prefLabel
Inmaculada Hernandez
@ast
Inmaculada Hernandez
@en
Inmaculada Hernandez
@es
Inmaculada Hernandez
@nl
Inmaculada Hernandez
@pl
P21
P31
P496
0000-0002-0118-4986